Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Stock
Equities
600329
CNE000001808
Pharmaceuticals
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
33.61 CNY | +0.09% | +1.51% | -0.12% |
Sales 2024 * | 9.05B 1.25B | Sales 2025 * | 9.96B 1.37B | Capitalization | 22.02B 3.04B |
---|---|---|---|---|---|
Net income 2024 * | 1.17B 162M | Net income 2025 * | 1.4B 193M | EV / Sales 2024 * | 2.43 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.21 x |
P/E ratio 2024 * |
22.1
x | P/E ratio 2025 * |
18.5
x | Employees | 4,619 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 31.08% |
1 day | +0.09% | ||
1 week | +1.51% | ||
Current month | +20.47% | ||
1 month | +19.99% | ||
3 months | +11.25% | ||
6 months | +12.00% | ||
Current year | -0.12% |
Managers | Title | Age | Since |
---|---|---|---|
Lei Wang
CEO | Chief Executive Officer | 53 | 22-08-21 |
Hong Zhou
CTO | Chief Tech/Sci/R&D Officer | 54 | 12-11-30 |
42 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Ping Zhang
BRD | Director/Board Member | 55 | 19-09-29 |
Yoke Pheng Liew
BRD | Director/Board Member | 68 | 20-06-04 |
Hong Zhou
CTO | Chief Tech/Sci/R&D Officer | 54 | 12-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +2.22% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 33.61 | +0.09% | 5,878,664 |
24-04-24 | 33.58 | +1.21% | 6,715,129 |
24-04-23 | 33.18 | -0.69% | 8,390,897 |
24-04-22 | 33.41 | +0.88% | 10,611,810 |
24-04-19 | 33.12 | +0.03% | 10,140,810 |
End-of-day quote Shanghai S.E., April 24, 2024
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-0.12% | 3.04B | |
+37.37% | 6.02B | |
-15.69% | 4.49B | |
-12.46% | 3.06B | |
+0.47% | 2.61B | |
+36.06% | 1.81B | |
+0.84% | 1.66B | |
-10.60% | 1.63B | |
-12.03% | 1.55B | |
+36.40% | 1.41B |
- Stock Market
- Equities
- 600329 Stock